With more than 25 years of experience, David Manspeizer represents industry-leading, global pharmaceutical and biotechnology companies in complex patent litigation. His experience combines over seven years as vice president – intellectual property and associate general counsel at pharmaceutical and biotechnology company Wyeth with more than 15 years at global law firms as an intellectual property litigator.
Mr. Manspeizer also advises clients on due diligence, validity, and infringement issues, and provides strategic patent portfolio advice. He is experienced in handling trademark and trade-secrets matters, as well as the IP aspects of licensing and other transactional matters, including settlements. Additionally, Mr. Manspeizer acts as a technical advisor to Judge Rodney Gilstrap in the Eastern District of Texas.
Prior to joining Morrison & Foerster, Mr. Manspeizer was a partner in the IP litigation practice of a leading global law firm, where he led litigation teams in Hatch-Waxman litigation for branded pharmaceutical companies and counseled clients on diligence and IP strategy. From 2002–2009, he was chief intellectual property officer for Wyeth, where he was responsible for all of the company’s patent, trademark, copyright, and trade-secrets matters, including all of its IP litigation matters. He was also responsible for supervising diligence, counseling, strategy, the IP aspects of transactions, and public policy for the corporate and pharmaceutical, consumer, and animal health divisions. While managing the department and overseeing all outside counsel activities, Mr. Manspeizer supervised multiple simultaneous U.S. and foreign patent and trademark litigations, including Hatch-Waxman and other litigation concerning the company’s blockbuster Effexor® XR, Protonix®, and Enbrel® products. He also led the effort that resulted in the decision in Wyeth v. Kappos, which effected a major change in the way that patent term adjustment is calculated. He also led royalty buyouts for a multibillion-dollar biologic product, designed the litigation and settlement strategy for a third-party suit alleging patent infringement by a multibillion-dollar product, and directed a strategic patent portfolio focus that yielded a top ranking on the Wall Street Journal’s patent scorecard for eight consecutive quarters (2007–2009).
Mr. Manspeizer began his legal career as an IP litigator at an international intellectual property law firm, where he spent 11 years and was a partner since 1999. There, he handled pharmaceutical and biotechnology patent litigation in U.S. district courts, the U.S. Court of Appeals for the Federal Circuit, and the U.S. International Trade Commission.
Mr. Manspeizer is named an IP Star by Euromoney Legal Media Group’s Managing IP 2014–16 and 2018–2019 and a "Patent Star" by LMG Life Sciences in 2018. He is also recommended by Legal 500 US 2017 in the practice area of Patent Litigation. He received his B.A. in biology from the University of Pennsylvania and his J.D. from Rutgers University School of Law.
Mr. Manspeizer is admitted to practice in New York, New Jersey, and the District of Columbia, as well as before the Court of Appeals for the Federal Circuit and the United States Supreme Court. He is also registered to practice before the United States Patent and Trademark Office.
Mr. Manspeizer is named an IP Star by Euromoney Legal Media Group’s Managing IP 2014–16 and 2018–2019 and a "Patent Star" by LMG Life Sciences in 2018. He is also recommended by Legal 500 US 2017 in the practice area of Patent Litigation.
©1996-2018 Morrison & Foerster LLP. All rights reserved.